Immunobiology of acute graft-versus-host disease - PubMed (original) (raw)
Review
Immunobiology of acute graft-versus-host disease
Pavan Reddy et al. Blood Rev. 2003 Dec.
Abstract
Graft-versus-host disease (GVHD) has been the primary limitation to the wider application of allogeneic bone marrow transplantation (BMT). The immunobiology of acute GVHD is complex and can be conceptualized to be a three-step process. In step 1, the conditioning regimen (irradiation and/or chemotherapy) leads to the damage and activation of host tissues and induces the secretion of inflammatory cytokines TNF-alpha and IL-1. As a consequence expression of MHC antigens and adhesion molecules is increased, thus enhancing the recognition of host alloantigens by donor T cells. Donor T-cell activation in step 2 is characterized by donor T-cell interaction with host APCs and subsequent proliferation, differentiation, and secretion of cytokines. Cytokines such as IL-2 and IFN-gamma enhance T-cell expansion, induce cytotoxic T cells (CTL) and natural killer (NK) cell responses, and prime additional mononuclear phagocytes to produce TNF-alpha and IL-1. These inflammatory cytokines in turn stimulate production of inflammatory chemokines, thus recruiting effector cells into target organs. In step 3, effector functions of mononuclear phagocytes are triggered via a secondary signal provided by lipopolysaccharide (LPS) that leaks through the intestinal mucosa damaged during step 1. This mechanism may result in the amplification of local tissue injury and further promotion of an inflammatory response, which, together with the CTL and NK components, leads to target tissue destruction in the transplant host.
Similar articles
- Pathophysiology of acute graft-versus-host disease.
Reddy P. Reddy P. Hematol Oncol. 2003 Dec;21(4):149-61. doi: 10.1002/hon.716. Hematol Oncol. 2003. PMID: 14735553 Review. - Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia.
Hill GR, Teshima T, Gerbitz A, Pan L, Cooke KR, Brinson YS, Crawford JM, Ferrara JL. Hill GR, et al. J Clin Invest. 1999 Aug;104(4):459-67. doi: 10.1172/JCI6896. J Clin Invest. 1999. PMID: 10449438 Free PMC article. - Cellular and cytokine effectors of acute graft versus host disease.
Ferrara JL. Ferrara JL. Int J Hematol. 2002 Aug;76 Suppl 1:195-8. doi: 10.1007/BF03165244. Int J Hematol. 2002. PMID: 12430853 - The pathophysiology of acute graft-versus-host disease.
Ferrara JL, Cooke KR, Teshima T. Ferrara JL, et al. Int J Hematol. 2003 Oct;78(3):181-7. doi: 10.1007/BF02983793. Int J Hematol. 2003. PMID: 14604275 Review. - Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease.
Cooke KR, Hill GR, Crawford JM, Bungard D, Brinson YS, Delmonte J Jr, Ferrara JL. Cooke KR, et al. J Clin Invest. 1998 Nov 15;102(10):1882-91. doi: 10.1172/JCI4285. J Clin Invest. 1998. PMID: 9819375 Free PMC article.
Cited by
- Better clinical outcomes and lower triggering of inflammatory cytokines for allogeneic hematopoietic cell transplant recipients treated in home care versus hospital isolation - the Karolinska experience.
Ringdén O, Svahn BM, Moll G, Sadeghi B. Ringdén O, et al. Front Immunol. 2024 Aug 7;15:1384137. doi: 10.3389/fimmu.2024.1384137. eCollection 2024. Front Immunol. 2024. PMID: 39170616 Free PMC article. Review. - Human amniotic epithelial stem cell is a cell therapy candidate for preventing acute graft-versus-host disease.
Yang PJ, Zhao XY, Kou YH, Liu J, Ren XY, Zhang YY, Wang ZD, Ge Z, Yuan WX, Qiu C, Tan B, Liu Q, Shi YN, Jiang YQ, Qiu C, Guo LH, Li JY, Huang XJ, Yu LY. Yang PJ, et al. Acta Pharmacol Sin. 2024 May 27. doi: 10.1038/s41401-024-01283-y. Online ahead of print. Acta Pharmacol Sin. 2024. PMID: 38802569 - Understanding and treatment of cutaneous graft-versus-host-disease.
Hong J, Fraebel J, Yang Y, Tkacyk E, Kitko C, Kim TK. Hong J, et al. Bone Marrow Transplant. 2023 Dec;58(12):1298-1313. doi: 10.1038/s41409-023-02109-x. Epub 2023 Sep 20. Bone Marrow Transplant. 2023. PMID: 37730800 Review. - Combinatorial inhibition of Tec kinases BTK and ITK is beneficial in ameliorating murine sclerodermatous chronic graft versus host disease.
Palaniyandi S, Strattan E, Kumari R, Mysinger M, Hakim N, Kesler MV, Apatira M, Bittencourt F, Wang L, Jia Z, Gururaja TL, Hill RJ, Hildebrandt GC. Palaniyandi S, et al. Bone Marrow Transplant. 2023 Aug;58(8):924-935. doi: 10.1038/s41409-023-02001-8. Epub 2023 May 9. Bone Marrow Transplant. 2023. PMID: 37160943 - Rapid cardiovascular aging following allogeneic hematopoietic cell transplantation for hematological malignancy.
Dillon HT, Foulkes S, Horne-Okano YA, Kliman D, Dunstan DW, Daly RM, Fraser SF, Avery S, Kingwell BA, La Gerche A, Howden EJ. Dillon HT, et al. Front Cardiovasc Med. 2022 Dec 15;9:926064. doi: 10.3389/fcvm.2022.926064. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36588564 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous